RNS Number : 4033S AstraZeneca PLC 27 August 2026     27 August 2026  Tezspire demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints  Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52    Efficacy in a third epithelial-driven inflammatory disease supports broad potential…

RNS Number : 9588R AstraZeneca PLC 25 August 2026     25 August 2026   AstraZeneca prices €2.55 billion bond offering   AstraZeneca PLC (the Company) announces that, on 24 August 2026, its wholly owned subsidiary AstraZeneca Finance LLC, successfully priced four tranches of Eurobonds totalling €2.55 billion (the Offering). The Offering is expected to close on 1 September…

RNS Number : 8414Q AstraZeneca PLC 17 August 2026   17 August 2026 Tagrisso plus Orpathys demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on Tagrisso First global Phase III trial to show significant progression-free and overall survival benefits in this setting   SAFFRON trial…

RNS Number : 8416Q AstraZeneca PLC 17 August 2026   17 August 2026   Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial   AstraZeneca and Daiichi Sankyo’s Enhertu is the first and only HER2-directed medicine…

RNS Number : 8415Q AstraZeneca PLC 17 August 2026   17 August 2026 Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer   AstraZeneca is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig in combination with chemotherapy as a 1st-line therapy compared to pembrolizumab and chemotherapy in patients…